Melatonin supplements can increase involuntary leg movements in people who already have restless legs syndrome, according to a small but carefully designed study. The effect is real and measurable, but the evidence base is thin, and the relationship between melatonin and RLS is more layered than a simple cause-and-effect story. Whether melatonin triggers new cases of RLS in people who have never experienced it is an even murkier question, with almost no direct research to draw on.
What the Research Actually Shows
The most direct evidence comes from a study of eight people with severe RLS. Researchers gave each participant 3 mg of melatonin in the evening and measured their periodic leg movements during a standardized immobilization test, both one hour and four and a half hours after the dose. Compared to a baseline session with no melatonin, the participants showed a significant increase in periodic leg movements after taking the supplement.1PubMed. Effects of melatonin and bright light administration on motor and sensory symptoms of RLS
That finding sounds alarming on its own, but there is an odd wrinkle: despite moving their legs more, the participants did not report feeling any increase in discomfort or the unpleasant sensations that characterize RLS.2PubMed Central. Chronic Administration of Melatonin: Physiological and Clinical Considerations This is a strange disconnect. The hallmark misery of RLS is the creeping, pulling, or tingling sensations that drive the urge to move. If those sensations do not get worse while the movements do, the clinical meaning is less clear. It could mean melatonin nudges the motor system toward more involuntary activity without actually worsening the subjective experience, or it could mean eight people were too few to detect a difference in self-reported symptoms.
Either way, this is a single small study. It was well designed for what it set out to measure, but eight participants with severe RLS is a narrow window into a condition that affects roughly 5 to 10 percent of adults to varying degrees. No large trial has followed up on the question, so the finding stands as a signal worth paying attention to, not a settled verdict.
Why Melatonin Might Affect Leg Movements
RLS has a striking circadian pattern. Symptoms reliably worsen in the evening and peak during the nighttime hours, easing by morning. Researchers have spent years trying to figure out why this happens, and the list of suspects includes iron metabolism in the brain, dopamine signaling, and, yes, melatonin itself.3PubMed Central. Circadian rhythm in restless legs syndrome
The leading theory for RLS involves dopamine, a neurotransmitter that helps regulate movement. Dopamine levels in certain brain areas follow a daily cycle, dipping in the evening and overnight. In people with RLS, something about this normal dip appears to trigger or amplify the uncomfortable leg sensations. Iron plays a role too, because the brain needs iron to produce dopamine efficiently, and brain iron levels also fluctuate across the day.
Melatonin fits into this picture because it is part of the same circadian machinery. The pineal gland ramps up melatonin production as darkness falls, signaling the body that it is time to wind down. When you take a melatonin supplement in the evening, you are adding to that natural rise, potentially amplifying whatever downstream effects melatonin has on dopamine pathways. There is evidence from animal studies that melatonin can inhibit dopamine release in certain brain regions. If that holds true in humans, it would explain why an extra dose of melatonin might push the dopamine system further into the low range that aggravates RLS.
This does not mean melatonin causes RLS outright. The condition has strong genetic underpinnings, with multiple gene variants associated with increased risk. What melatonin appears capable of doing is worsening symptoms in people whose dopamine system is already primed to produce them. Think of it as adding weight to one side of an already tipping scale, rather than building the scale from scratch.
Melatonergic Medications Tell a Similar Story
Some indirect evidence comes from medications that act on melatonin receptors. Agomelatine is an antidepressant used in some countries that works partly by stimulating melatonin receptors and partly by blocking a specific serotonin receptor. In at least one documented case, a patient developed RLS symptoms within two days of starting agomelatine. The symptoms were classic: unpleasant leg sensations that worsened at night, with an urge to move. After the drug was stopped, symptoms improved within 24 hours and resolved completely within four days.4PubMed Central. Suspected Agomelatine-induced restless legs syndrome: a case report
A single case report is about as weak as evidence gets, and the authors acknowledged this was the first time anyone had reported agomelatine triggering RLS. The patient was also taking escitalopram, an SSRI antidepressant, which makes the picture messier because SSRIs themselves are known to sometimes provoke or worsen RLS. Still, the rapid onset after starting agomelatine and equally rapid resolution after stopping it scored as a “probable” adverse drug reaction on a standardized scale used to evaluate such things.
The relevance to over-the-counter melatonin is indirect. Agomelatine is not the same as taking a melatonin pill. It binds to melatonin receptors more potently and more selectively, and it has additional pharmacological effects. But the case does reinforce the broader pattern: stimulating the melatonin system, whether through supplements or through prescription drugs, may have the potential to provoke leg symptoms in susceptible people.
Bright Light and the Flip Side of the Coin
The same study that tested melatonin on those eight RLS patients also tested the opposite intervention: bright light exposure, which is well known to suppress the body’s natural melatonin production. Participants were exposed to bright light before the immobilization test, and the results were intriguing. Bright light did not change the number of periodic leg movements compared to baseline, but it did produce a small, statistically significant decrease in sensory symptoms.1PubMed. Effects of melatonin and bright light administration on motor and sensory symptoms of RLS
This is an interesting asymmetry. Melatonin increased leg movements without worsening sensory discomfort, while bright light decreased sensory discomfort without reducing leg movements. The motor and sensory components of RLS seem to be responding to different parts of the melatonin system, or perhaps to different mechanisms entirely that just happen to correlate with melatonin levels.
For people looking for practical help, the bright light finding has been picked up by some sleep researchers as a potential non-drug approach worth exploring. Spending time under bright, full-spectrum light in the early evening might modestly ease the sensory component of RLS. However, this too comes from a very small study, and bright light in the evening carries its own trade-off: it can delay sleep onset by suppressing the melatonin surge you need to feel drowsy. For someone taking melatonin specifically because they struggle to fall asleep, replacing it with bright light would defeat the purpose.
Conditions That Look Like RLS but Are Not
If you have started taking melatonin and noticed new leg discomfort at night, it is worth considering whether what you are experiencing is actually RLS or something else. Several conditions produce similar-sounding symptoms but differ in important ways. Nocturnal leg cramps, for example, involve sudden, painful muscle contractions rather than the creeping or pulling sensations of RLS. Sleep starts, those involuntary jerks you sometimes feel as you drift off, are brief and do not involve an urge to move. Neuroleptic-induced akathisia, a side effect of certain psychiatric medications, produces a generalized restlessness that is not confined to the legs and does not follow RLS’s characteristic circadian pattern.5Sleep Medicine. RLS-like symptoms: differential diagnosis by history and clinical assessment
The distinguishing features of true RLS are fairly specific: an urge to move the legs accompanied by uncomfortable sensations, worsening during rest or inactivity, relief with movement, and a clear pattern of symptoms being worse in the evening and at night. If what you are feeling does not fit all four of those criteria, the problem may lie elsewhere. This matters because the treatments for RLS are quite different from those for cramps, akathisia, or other nighttime leg complaints, and jumping to the wrong diagnosis leads to the wrong treatment.
Should You Stop Taking Melatonin?
If you have diagnosed RLS and are taking melatonin for sleep, the evidence suggests a reason for caution but not necessarily panic. The increase in leg movements seen in the study was measured by instruments, not reported by the patients themselves as worse symptoms. That said, everyone’s experience differs, and a measurable increase in periodic leg movements can disrupt sleep architecture even if you do not consciously feel more discomfort. Fragmented sleep from leg movements you do not fully wake up for can leave you tired the next day without an obvious explanation.
A reasonable approach is to pay attention to timing. If your RLS symptoms worsened after you started taking melatonin, try stopping it for a week or two and see if things improve. The supplement clears your system quickly, so any melatonin-related worsening should reverse within a few days, similar to the resolution seen in the agomelatine case report. If your symptoms stay the same whether or not you take melatonin, the supplement probably is not your problem.
Dose matters too, though we have almost no dose-response data for melatonin and RLS specifically. The study used 3 mg, which is a standard over-the-counter dose in many countries but is actually much higher than what the body produces naturally. Physiological doses, in the range of 0.3 to 0.5 mg, might have a different effect, though nobody has tested this in RLS patients. Some sleep researchers have argued for years that most people take far more melatonin than they need, and using a lower dose might reduce side effects across the board while still being effective for sleep onset.
Other Medications That Can Worsen RLS
Melatonin gets a lot of attention because it is ubiquitous and available without a prescription, but it is far from the only substance that can aggravate restless legs. Several classes of medication are well established as potential RLS triggers or amplifiers, and awareness of these is arguably more important than worrying about melatonin.
Antihistamines, particularly the older sedating types found in many over-the-counter sleep aids and allergy medications, are common culprits. Diphenhydramine, the active ingredient in products marketed for nighttime sleep, can worsen RLS for some people, which creates an unfortunate irony: someone with RLS-related insomnia reaches for a sleep aid that makes the underlying problem worse. Many antidepressants, especially SSRIs and SNRIs, are also associated with RLS worsening. Anti-nausea drugs that block dopamine receptors, such as metoclopramide, are particularly problematic because they directly interfere with the dopamine signaling thought to underlie RLS.
If you are dealing with RLS and take any of these medications, that is a conversation worth having with your doctor. In some cases, a switch to an alternative within the same drug class can make a significant difference. The broader point is that melatonin sits on a spectrum of substances that can modulate RLS symptoms, and it is not the most potent offender on the list by a long shot.
Newer Directions in RLS Treatment
For people with RLS who need help sleeping but want to avoid melatonin, the treatment landscape is evolving. Dopamine-related medications have been the standard first-line therapy for moderate to severe RLS for years, but long-term use comes with a well-known complication called augmentation, where the medication gradually makes symptoms worse rather than better. This has pushed researchers to look for alternatives that work through entirely different pathways.
One area of active research involves orexin receptor antagonists, a class of drugs originally developed for insomnia. A proof-of-concept study tested suvorexant, an orexin antagonist already approved for insomnia, in adults with idiopathic RLS to see whether it could address both sleep disruption and RLS symptoms simultaneously.6PubMed. Treatment of Sleep, Motor and Sensory Symptoms with the Orexin Antagonist Suvorexant in Adults with Idiopathic Restless Legs Syndrome The concept is appealing because orexin drugs tackle insomnia through a mechanism unrelated to melatonin or dopamine, potentially sidestepping the problems associated with both.
Iron supplementation is another approach with growing support, particularly for people whose ferritin levels are on the low side. Brain iron deficiency is increasingly recognized as a driver of RLS symptoms, and some guidelines now recommend checking ferritin levels and supplementing when they fall below a certain threshold, even if those levels would be considered “normal” by standard lab ranges. For someone whose RLS is partly driven by low iron, correcting the deficiency can reduce symptoms enough that sleep aids become unnecessary.
Why the Evidence Is So Thin
It is worth stepping back and acknowledging how little we actually know about melatonin and RLS. The pivotal study had eight participants. The agomelatine case report involved one person. There are no large trials, no dose-response studies, and no long-term data. This is not because the question is unimportant. Melatonin is one of the most widely used supplements in the world, and RLS is common enough that millions of people are potentially taking melatonin while living with the condition.
The gap exists partly because melatonin, as a supplement, does not have the pharmaceutical industry infrastructure behind it that funds large clinical trials. Nobody holds a patent on melatonin, so nobody stands to profit from a definitive trial. Academic researchers can apply for grants to study the question, but RLS itself competes for funding with conditions that affect more people or carry higher mortality risk. The result is that clinicians and patients are left making decisions based on biological plausibility and a handful of small studies rather than the kind of robust evidence available for, say, cholesterol-lowering drugs.
This does not mean the existing evidence should be dismissed. Small studies can identify real effects, and the biological rationale linking melatonin to dopamine suppression and circadian worsening of RLS is coherent. But it does mean that confident, sweeping claims in either direction, whether “melatonin causes restless legs” or “melatonin is perfectly safe for RLS patients,” go beyond what the science currently supports. The honest answer lives in the middle: there is a plausible mechanism and a small amount of experimental evidence suggesting melatonin can worsen leg movements in people with existing RLS, but the clinical significance of that finding remains genuinely uncertain.